LL-37 Research Guide Ireland

Overview

LL-37 is a 37-amino acid amphipathic alpha-helical peptide and the only member of the cathelicidin family of antimicrobial peptides found in humans. It is proteolytically cleaved from its precursor protein, hCAP-18 (human cationic antimicrobial protein 18), and is produced by neutrophils, macrophages, epithelial cells of the skin and respiratory tract, and other cell types as part of the innate immune system's first line of defence against pathogens. Research on LL-37 spans direct antimicrobial activity against bacteria, fungi, and some viruses, as well as its role as an immunomodulatory molecule that influences chemotaxis, wound healing, and angiogenesis. It has also been studied in the context of specific disease states including cystic fibrosis, rosacea, and chronic wounds, where its expression or regulation appears dysregulated. This guide is for educational and research purposes only. Not medical advice.

Clinical & Research Status

Evidence Type	Status
Human RCT	✗
Observational	✔
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗

Mechanism of Action

LL-37 is a cationic, amphipathic peptide that exerts direct antimicrobial activity primarily through interaction with negatively charged microbial cell membranes. Its positive charge and amphipathic helical structure allow it to insert into and disrupt lipid bilayers of bacteria, some fungi, and enveloped viruses, leading to membrane permeabilization and microbial cell death. This mechanism is broadly similar to other cationic antimicrobial peptides but LL-37 additionally shows immunomodulatory activity that extends well beyond direct pathogen killing. Independent of its antimicrobial function, LL-37 has been studied for its ability to bind and neutralize bacterial lipopolysaccharide (LPS), modulate Toll-like receptor signalling, act as a chemoattractant for neutrophils, monocytes, and T cells (partly via the formyl peptide receptor FPR2/ALX and purinergic receptor P2X7), and promote angiogenesis and re-epithelialization in wound tissue. Research has also implicated LL-37 in the formation of complexes with self-DNA and self-RNA that can activate plasmacytoid dendritic cells via Toll-like receptor 9 and 7 pathways, a mechanism explored in the context of autoimmune and inflammatory skin conditions such as psoriasis and rosacea.

Research Areas & Reported Effects

Direct Antimicrobial Activity

In vitro studies consistently demonstrate LL-37's broad-spectrum activity against Gram-positive and Gram-negative bacteria, including some antibiotic-resistant strains, as well as certain fungi and enveloped viruses. Research has explored minimum inhibitory concentrations across pathogen panels and the peptide's synergy with conventional antibiotics.

Wound Healing and Angiogenesis

LL-37 has been studied for its role in promoting keratinocyte migration, re-epithelialization, and new blood vessel formation in models of cutaneous wound repair. Research has examined reduced LL-37 expression in chronic non-healing wounds (such as venous leg ulcers) compared with acute healing wounds, suggesting a link between cathelicidin levels and wound repair capacity.

Cystic Fibrosis and Airway Research

Because the airway surface in cystic fibrosis presents an environment that can impair antimicrobial peptide function (partly due to altered salt concentration and mucus viscosity), LL-37 has been investigated in this context for its antibacterial activity against pathogens common in CF airways, such as Pseudomonas aeruginosa, and how airway conditions affect its efficacy.

Rosacea and Inflammatory Skin Signalling

Elevated and abnormally processed LL-37 (via dysregulated cathelicidin and kallikrein-5 protease activity) has been implicated in the pathophysiology of rosacea in preclinical and translational research, contributing to the characteristic inflammation and vascular changes of the condition. This has made LL-37 a target of interest for understanding rosacea pathogenesis rather than as a therapeutic candidate itself.

Research Data Summary

Study / Model	Reported Effect
In Vitro Antimicrobial Panels	Reported broad-spectrum bactericidal activity against Gram-positive and Gram-negative organisms at low micromolar concentrations, varying by species and strain.
Rodent Cutaneous Wound Models	Reported accelerated wound closure and increased vascularization associated with LL-37 expression or exogenous application.
Chronic Wound Tissue (Human Observational)	Reported reduced LL-37 expression in chronic venous leg ulcers compared with normally healing acute wounds.
Rosacea Skin Biopsy Studies (Human Observational)	Reported abnormally elevated and aberrantly processed cathelicidin peptide fragments in rosacea-affected skin compared with healthy controls.
Cystic Fibrosis Airway Surface Liquid Models	Reported reduced antimicrobial efficacy of LL-37 under high-salt conditions mimicking CF airway surface liquid, informing airway defence research.

Stack Combinations Studied

• LL-37 + conventional antibiotics (research comparator/combination design) → Research rationale: In vitro studies have explored whether LL-37 exhibits synergistic or additive antimicrobial effects when combined with standard antibiotics against resistant bacterial strains.
• LL-37 + other antimicrobial peptides (e.g., defensins) → Research rationale: Investigated in innate immunity research for combinatorial or synergistic antimicrobial and immunomodulatory effects reflecting how multiple host defence peptides act together physiologically.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
In Vitro Antimicrobial Assay Protocol	Low micromolar range (assay-dependent, typically 1-50 µM)	Hours (standard MIC/MBC assay timeframes)	Single exposure per assay design	Minimum inhibitory/bactericidal concentration determination against pathogen panels.
Rodent Topical Wound Model Protocol	Species- and formulation-dependent (µg to low mg per application reported in literature)	Days to 2-3 weeks	Daily topical application in published models	Wound closure rate and angiogenesis assessment.

Observed Side Effects in Research

• No consistent systemic adverse effects reported in in vitro or topical animal research at studied concentrations
• Cytotoxicity to host cells reported at higher concentrations in some in vitro assays, a key limitation in translating LL-37 to a direct therapeutic agent
• No completed human RCT safety data available for exogenous LL-37 administration

LL-37 research to date is dominated by in vitro, ex vivo, and observational human tissue studies rather than interventional human trials of exogenous LL-37 administration. Reported findings on inflammatory skin conditions such as rosacea concern LL-37's endogenous dysregulation as a disease mechanism, not a treatment application, and should not be interpreted as evidence for supplementation.

Compound Data

CAS Number

171833-49-5

Molecular Formula

C₂₀₅H₃₄₀N₆₀O₅₃ (approximate, 37-residue peptide)

Molecular Weight

Approximately 4493 g/mol

Half-Life

Short in biological fluids; rapidly processed and susceptible to proteolytic degradation in vivo

Synonyms

Cathelicidin antimicrobial peptide, hCAP-18 (37-residue active fragment), CAMP gene product

Research Classification

Human cathelicidin, Cationic antimicrobial and immunomodulatory peptide

Scientific References

• [Durr UH, Sudheendra US, Ramamoorthy A 2006] — LL-37, the only human member of the cathelicidin family of antimicrobial peptides. — Biochimica et Biophysica Acta — [Review / Mechanistic]
• [Heilborn JD et al. 2003] — The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. — Journal of Investigative Dermatology — [Human Observational]
• [Yamasaki K et al. 2007] — Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. — Nature Medicine — [Human Observational / In vitro]
• [Koczulla R et al. 2003] — An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. — Journal of Clinical Investigation — [Animal / In vitro]
• [Bals R et al. 1998] — Human cathelicidin, hCAP-18, is expressed in bronchial epithelium and airway secretions. — American Journal of Respiratory Cell and Molecular Biology — [Human / In vitro]
• [Bucki R et al. 2007] — Salt-dependent regulation of antimicrobial peptide LL-37 activity in airway surface liquid of cystic fibrosis. — Journal of Cystic Fibrosis literature — [In vitro]

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*